Sickle cell anemia: new combo therapy shows promise for higher hemoglobin
NCT ID NCT05451940
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This early-phase study tested whether adding erythropoietin (EPO) to standard hydroxyurea treatment can safely raise hemoglobin levels in adults with sickle cell disease. Seventeen participants with chronic anemia received the combination for 12 weeks. The main goal was to see if at least a 1 g/dL increase in hemoglobin occurred, which could reduce the need for blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lagos University Teaching Hospital
Lagos, 102215, Nigeria
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.